Recombinant RSV virus expression systems and vaccines

Details Recombinant RSV virus expression systems and vaccines Recombinant RSV virus expression systems and vaccines

2005-03-11

2008-12-16

Lucas, Zachariah (Department: 1648)

Chemistry: molecular biology and microbiology

Virus or bacteriophage, except for viral vector or...

Inactivation or attenuation; producing viral subunits

C435S235100, C435S239000, C536S023700, C536S023720

Reexamination Certificate

active

07465574

ABSTRACT:
The present invention relates to genetically engineered recombinant RS viruses and viral vectors which contain heterologous genes which for the use as vaccines. In accordance with the present invention, the recombinant RS viral vectors and viruses are engineered to contain heterologous genes, including genes of other viruses, pathogens, cellular genes, tumor antigens, or to encode combinations of genes from different strains of RSV.

REFERENCES:
patent: 5166057 (1992-11-01), Palese et al.
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5840520 (1998-11-01), Clarke et al.
patent: 5843451 (1998-12-01), Compans et al.
patent: 5993824 (1999-11-01), Murphy et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6060308 (2000-05-01), Parrington
patent: 6168943 (2001-01-01), Rose
patent: 6264957 (2001-07-01), Collins
patent: 6830748 (2004-12-01), Jin et al.
patent: 6923971 (2005-08-01), Krempl et al.
patent: 2003/0027321 (2003-02-01), Jin et al.
patent: 2004/0234506 (2004-11-01), Jin et al.
patent: 2005/0084947 (2005-04-01), Jin et al.
patent: 2005/0158340 (2005-07-01), Jin et al.
patent: 0 440 219 (1991-08-01), None
patent: 94202089.2 (1994-07-01), None
patent: 0 780 475 (1999-06-01), None
patent: WO 91/03552 (1991-03-01), None
patent: WO 93/06218 (1993-04-01), None
patent: WO 95/08634 (1995-03-01), None
patent: WO 96/10632 (1996-04-01), None
patent: WO 96/40945 (1996-12-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 98/02179 (1998-01-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 98/50405 (1998-11-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 99/15631 (1999-04-01), None
patent: WO 99/57284 (1999-11-01), None
patent: WO 99/63064 (1999-12-01), None
patent: WO 00/18929 (2000-04-01), None
patent: WO 00/53786 (2000-09-01), None
Tang et al., “Requirement of cysteines and length of the human respiratory syncytial virus M2-1 protein for protein function and virus viability,” Journal of Virology, vol. 75 No. 23, pp. 11328-11335 (Dec. 2001).
U.S. Appl. No. 09/724,388, filed Nov. 28, 2000, Jin et al.
U.S. Appl. No. 09/724,416, filed Nov. 28, 2000, Jin et al.
U.S. Appl. No. 11/389,618, filed Mar. 24, 2006, Jin et al.
Atreya, P. L. et al.,1998, “The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription of RNA replication,” J. Virol. 72:1452-1461.
Baer et al., 1990, “Rhabdoviruses,” Virology, 2nded., Fields et al., eds., Raven Press Ltd., New York, pp. 883, 887.
Ballart (Eschle) et al., 1991, “Retraction: Infectious measles virus from cloned cDNA,” EMBO J. 10(11):3558.
Ballart et al., 1990, “Infectious measles virus from cloned cDNA,” EMBO J. 9(2):379-384.
Baron et al., 1997, “Rescue of rinderpest virus from cloned cDNA,” J. virol. 71:1265-1271.
Beeler et al., 1988, “Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function” J. Virol. 63:2941-2950.
Belshe et al., 1992, “Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children,” J. Clin. Microbiol. 30(8):2064-2070.
Brown et al., 1967 , “Infective Virus Substructure from Vesicular Stomatitis Virus,” J. Virol. 1:368-373.
Bucholz et al., 1999, “Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as functional BRSV genome promoter,” J. Virol. 73(1):251-259.
Bukreyev et al. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol. Dec. 1997;71(12):8973-82.
Bukreyev et al. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J Virol. Oct. 1996;70(10):6634-41.
Calain et al., 1993, “The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA,” J. Virol. 67(8):4822-4830.
Calain et al., 1992, “Molecular cloning of natural paramyxovirus copy-back defective interfering RNAs and their expression from DNA,” Virol. 191:62-71.
Castrucci et al., 1995, “Reverse genetics system for generation of an influenza A virus mutant containing a deletion of the carboxyl-terminal residue of M2 protein,” J. Virol. 69(5):2725-2728.
Chin et al., 1969, “Field Evaluation of a Respiratory Syncytial Virus Vaccine and a Trivalent Parainfluenza Virus Vaccine in a Pediatric Population,” Am. J. Epidemiol. 89:449-463.
Coates, H.V. et al.,1966, “An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test,” AM. J. Epid. 83:299-313.
Collins et al., 1984, “Identification of a tenth mRNA of respiratory syncytial virus and assignment of polypeptides to the 10 viral genes,” J. Virol. 49:572-578.
Collins et al.,1990, “Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus,” Vaccine 8:164-168.
Collins, 1991, The paramyxoviruses pp. 103-162. D.W. Kingsbury (ed.) Plenum Press New York.
Collins et al., 1991, “Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene,” Proc. Natl. Acad. Sci. USA 88:9663-9667.
Collins et al., 1993, “Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNA,” Virology 195:252-256.
Collins et al., 1995, “Production of infectious human respiratory syncytial virus from cloned cDNA confirms' an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development,” Proc. Natl. Acad. Sci. USA 92:11563-11567.
Collins, P.L. et al., “Respiratory Syncytial Virus,” pp. 1313-1351 of vol. 1, Fields Virology, et al.,Eds. 3rd ed., Raven Press, 1996.
Collins, P. L. et al., 1996, “Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus,” Proc. Natl. Acad. Sci. U S A 93, 81-85.
Collins et al. Support plasmids and support proteins required for recovery of recombinant respiratory syncytial virus. Virology. Jul. 5, 1999;259(2):251-5.
Collins et al., 1999, “Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics,” Adv Virus Res. 54:423-51.
Crowe et al., 1994, “Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis,” Vaccine 12:691-699.
Crowe et al. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. Jul. 1994;12(9):783-790.
Crowe et al.,1995, “Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development,” Vaccine 13(4):415-421.
Crowe et al., 1996, “Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene,” Virus Genes 13(3):269-273.
Current Protocols in Molecular Biology, vol. 1: Chapter 9.6.2, 2005.
Deng et al., 1991, “High-efficiency protein synthesis from T7 RNA polymerase transcripts in 3T3 fibroblasts,” Gene 109(2):193-201.
Dimcock and Collins, 1993, “Rescue of synthetic analogs of

Affiliated with

Also associated with

Rating

Recombinant RSV virus expression systems and vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant RSV virus expression systems and vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant RSV virus expression systems and vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4033777